Olmibite-Trio 12.5 Tablet
Marketer
Medbiosquid Pharmaceuticals Pvt Ltd
Salt Composition
Olmesartan Medoxomil (20mg) + Cilnidipine (10mg) + Chlorthalidone (12.5mg)
Overview Olmibite-Trio 12.5 Tablet
Triomib 12.5mg tablets combine multiple medications to effectively manage hypertension when monotherapy proves insufficient. This formulation lowers elevated blood pressure, significantly reducing the risk of future strokes and heart attacks. Triomib 12.5mg should be administered with food, with dosage tailored to individual patient response and condition. Consistent daily timing is recommended. Continuous use, as directed by your physician, is crucial; discontinuation may increase stroke or heart attack risk. The formulation includes a diuretic, increasing urinary frequency; therefore, avoid dosing within four hours of bedtime. Regular intake, even during periods of wellness, maximizes therapeutic benefit, as hypertension often presents asymptomatically. Common side effects include edema in the ankles, headache, dizziness, fatigue, and altered taste perception. Report any persistent, worsening, or bothersome side effects to your doctor immediately. Adequate hydration helps mitigate potential side effects such as muscle weakness, xerostomia, and polydipsia. Prior to commencing treatment, inform your physician of any pre-existing liver or kidney conditions, and pregnant or breastfeeding individuals should seek medical counsel. Comprehensive disclosure of all current medications, especially those for hypertension or cardiac conditions, is essential. Regular monitoring of blood pressure, kidney function, electrolyte levels, and blood glucose is necessary to optimize treatment efficacy.
Primary Ingredients of Olmibite-Trio 12.5 Tablet
No information provided. Please provide the text you wish to be rephrased.
Uses of Olmibite-Trio 12.5 Tablet
Elevated arterial blood pressure
Major Benefits of Olmibite-Trio 12.5 Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. It's recommended to take Olmibite-Trio 12.5mg tablets with food.
Common Side effects of Olmibite-Trio 12.5 Tablet:
- Ankle swelling
- Headache
- Dizziness
- Tiredness
- Palpitations
- Sleepiness
- Increased blood uric acid
- Glucose intolerance
- Taste change
- Flushing (sense of warmth in the face, ears, neck and trunk)
- Upset stomach
- Altered blood lipid level
How to use Olmibite-Trio 12.5 Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the entire tablet without chewing, crushing, or fracturing it. It's recommended to take Olmibite-Trio 12.5mg tablets with food.
How Olmibite-Trio 12.5 Tablet works:
Each Olmibite-Trio 12.5 Tablet unites olmesartan medoxomil (an angiotensin receptor blocker or ARB), cilnidipine (a calcium channel blocker or CCB), and chlorthalidone (a diuretic). Olmesartan medoxomil and cilnidipine lower blood pressure by promoting vasodilation, relaxing blood vessels. Chlorthalidone reduces blood pressure by eliminating excess fluid and electrolytes via urination, while also contributing to vasodilation and improved circulation.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent use of Olmibite-Trio 12.5mg tablets and alcohol may result in significant sedation.
PregnancyCONSULT YOUR DOCTOR
Using Olmibite-Trio 12.5 mg tablets during pregnancy carries a confirmed risk to the fetus. Prescribing may occur exceptionally in life-threatening circumstances where potential benefits outweigh the known hazards. Physician consultation is essential.
Breast feedingCONSULT YOUR DOCTOR
Data on the safety of Olmibite-Trio 12.5 Tablet while breastfeeding is lacking. Seek medical advice from your physician.
DrivingUNSAFE
Taking Olmibite-Trio 12.5 mg tablets might cause drowsiness, blurred vision, or dizziness. Refrain from driving if you experience these effects.
KidneyCAUTION
Patients with severe kidney impairment should exercise caution when using Olmibite-Trio 12.5 mg tablets, as dose modification may be necessary. Consult a physician before use; administration is generally inadvisable for this patient population.
LiverCAUTION
Patients with liver impairment should use Olmibite-Trio 12.5 mg tablets cautiously, potentially requiring dosage modification. Medical advice is necessary. Olmibite-Trio 12.5 mg tablets are contraindicated in patients exhibiting severe hepatic dysfunction.
What if you forget to take Olmibite-Trio 12.5 Tablet :
Should you forget to take a dose of Olmibite-Trio 12.5 Tablet, administer it at your earliest convenience. If, however, your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Olmibite-Trio 12.5 Tablet
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Heart |



